Skip to main content

2023-24 Cytopathology Fellowship

Application Window

Open July 1st, 2021 through Friday, Dec 31, 2021 at 11:59pm (Pacific Time)

Position description

The David Geffen School of Medicine at UCLA, Department of Pathology offers a one-year fellowship program in cytopathology. The core responsibilities include performing superficial fine needle aspirations and on-site assessment of guided deep aspirates on both pediatric and adult patients, gaining advanced experience in diagnosis, teaching, and research in clinical cytopathology. Diagnostic material consists of a wide variety of gynecologic and non-gynecologic specimens.

Fellows are given increasing responsibility in cytopathology sign-out as they acquire experience and participate in teaching pathology residents, medical students, and cytotechnology students. They also gain experience with palpation-guided and ultrasound (US)-guided fine needle aspirations (FNA) in the department's FNA clinic. Research opportunities in immunocytochemistry, morphometry, and applied molecular pathology are available. Goals of the program are to provide advanced training in cytopathology and FNA using state-of-the-art supportive diagnostic techniques, to prepare for a career in academic or community cytopathology, and to prepare for the American Board of Pathology Added Qualification in Cytopathology exam. A variety of local and national educational conferences are available. There is an academic fund for each fellow to attend local or national meetings to present research endeavors.

We are participating in the American Society of Cytopathology (ASC) unified recruitment timeline for cytopathology fellowship programs for the 2023-2024 fellowship year starting on July 1, 2023. Applications will start being reviewed July 15, 2021. Interviews will start being offered August 15, 2021. Formal offers to applicants will begin October 1, 2021. Applicants offered a position will have 72 hours to accept or decline the offer.

These positions are open to applicants who have completed training in a US or Canadian ACGME accredited AP/CP or AP only residency program. Applicants must be Board eligible or Board certified. International medical school graduates will only be considered if they have completed residency training in a US or Canadian ACGME accredited residency program. A California medical license is required on Day One of appointment.

Qualifications

Basic qualifications (required at time of application)

    These positions are open to applicants who have completed training in a US or Canadian ACGME accredited AP/CP or AP only residency program. Applicant must be Board eligible or Board certified. International medical school graduates will only be considered if they have completed residency training in a US or Canadian ACGME accredited residency program. A California medical license is required on day one of appointment.

Application Requirements

Document requirements
  • Application - https://www.uclahealth.org/pathology/workfiles/Education/FellowshipApp_2018.pdf

  • Curriculum Vitae - Your most recently updated C.V.

  • Personal Statement

  • USMLE Steps I, II, III - Please scan all three steps into one PDF

  • Letter of Good Standing - Please provide a letter from your current PD. If your PD is a letter writer, they still have to provide the letter of good standing.

  • Photo (Optional)

  • Misc / Additional (Optional)

Reference requirements
  • 3-5 letters of reference required

Letters of recommendation
3 required; 2 optional (5 total)

Apply link: https://recruit.apo.ucla.edu/JPF06524

Help contact: xiaojianlu@mednet.ucla.edu

Campus Information

The University of California is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, age or protected veteran status. For the complete University of California nondiscrimination and affirmative action policy, see: UC Nondiscrimination & Affirmative Action Policy.